1682-44-6

Basic information

• Product Name: 3-(2-fluorophenyl)-1-(2-hydroxyphenyl)prop-2-en-1-one
• CAS NO: 1682-44-6
• Molecular Formula: C₁₅H₁₁FO₂
• Molecular Weight: 242.245
• Mol File: 1682-44-6.mol
• Article Data: 17

Chemical Properties

• Boiling Point: 394.8°C at 760 mmHg
• Flash Point: 192.5°C
• Density: 1.258g/cm³
• Vapor Pressure: 8.5E-07mmHg at 25°C
• Refractive Index: 1.635
• CAS DataBase Reference: 3-(2-fluorophenyl)-1-(2-hydroxyphenyl)prop-2-en-1-one(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(2-fluorophenyl)-1-(2-hydroxyphenyl)prop-2-en-1-one(1682-44-6)
• EPA Substance Registry System: 3-(2-fluorophenyl)-1-(2-hydroxyphenyl)prop-2-en-1-one(1682-44-6)

Safety Data

• Hazardous Substances Data: 1682-44-6(Hazardous Substances Data)

Upstream product

• 120681-05-2 o-Fluorocinnamoylchlorid 
• 108-95-2 phenol 
• 118-93-4 o-hydroxyacetophenone 
• 446-52-6 2-Fluorobenzaldehyde 

Downstream Products

• 1645-20-1 2'-Fluoroflavone 
• 59223-78-8 1-(2-hydroxy-phenyl)3-(2-fluoro-phenyl)-propan-1-one 
• 1956-95-2 2,3-dihydro-2-(2-fluorophenyl)-4H-1-benzopyran-4-one 
• 1439437-80-5 C₂₁H₂₆FNO₃ 
• 1443143-93-8 C₁₈H₁₇FO₃ 
• 364-24-9 3-hydroxy-2-(2-fluorophenyl)-chromen-4(1H)-one 

Relevant articles and documents

Mycobactin Analogues with Excellent Pharmacokinetic Profile Demonstrate Potent Antitubercular Specific Activity and Exceptional Efflux Pump Inhibition

In this study, we have designed and synthesized pyrazoline analogues that partially mimic the structure of mycobactin, to address the requirement of novel therapeutics to tackle the emerging global challenge of antimicrobial resistance (AMR). Our investigation resulted in the identification of novel lead compounds 44 and 49 as potential mycobactin biosynthesis inhibitors against mycobacteria. Moreover, candidates efficiently eradicated intracellularly surviving mycobacteria. Thermofluorimetric analysis and molecular dynamics simulations suggested that compounds 44 and 49 bind to salicyl-AMP ligase (MbtA), a key enzyme in the mycobactin biosynthetic pathway. To the best of our knowledge, these are the first rationally designed mycobactin inhibitors to demonstrate an excellent in vivo pharmacokinetic profile. In addition, these compounds also exhibited more potent whole-cell efflux pump inhibition than known efflux pump inhibitors verapamil and chlorpromazine. Results from this study pave the way for the development of 3-(2-hydroxyphenyl)-5-(aryl)-pyrazolines as a new weapon against superbug-associated AMR challenges.

A novel one-pot synthesis of flavones

In this paper, a one-pot facile route for the BiCl3/RuCl3-mediated synthesis of functionalized flavones is described, including: (i) intermolecularortho-acylation of substituted phenols with cinnamoyl chlorides, and (ii) intramolecular cyclodehydrogenation of the resultingo-hydroxychalcones. The reaction conditions are discussed herein.

Differences in antioxidant potential of chalcones in human serum: In vitro study

Introduction: An imbalance between oxidants and antioxidants in favour of oxidants, potentially leading to damage, is termed oxidative stress. Antioxidants (AO), either enzymatic or non-enzymatic, are the ones that can reduce diverse effects of pro-oxidan